Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹5,238 Cr
up ₹426 Cr vs Apr 2021
- Stocks held
- 22
- up 1 vs Apr 2021
- Top 10 weight
- 74.0%
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In May 2021 it disclosed 22 stocks worth ₹5,238 Cr, up ₹426 Cr from Apr 2021. Its largest positions were Dr. Reddy's Laboratories Limited (9.7%), Sun Pharmaceutical Industries Limited (9.6%), Cipla Limited (8.7%); the ten largest together made up 74.0% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 79.0% of its equity. Cash and debt stood at 5.9%. Compared with Apr 2021 the fund entered 1 new stock and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
95%
Top-10 weight is higher than 95% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
78%
Holds more cash than 78% of peers
What these mean: concentration · cash
Holdings in May 2021
Download CSVEvery line the fund disclosed, with the change against Apr 2021. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Dr. Reddy's Laboratories Limited | 9.73% | down 0.20 pts | ₹510 Cr | up ₹32.1 Cr | Added |
| Sun Pharmaceutical Industries Limited | 9.57% | down 1.31 pts | ₹501 Cr | down ₹22.3 Cr | Trimmed |
| Cipla Limited | 8.70% | down 0.38 pts | ₹456 Cr | up ₹18.7 Cr | Added |
| Aurobindo Pharma Limited | 8.57% | down 1.21 pts | ₹449 Cr | down ₹21.7 Cr | Trimmed |
| Divi's Laboratories Limited | 8.41% | down 0.46 pts | ₹440 Cr | up ₹13.8 Cr | Added |
| Lupin Limited | 7.92% | down 0.98 pts | ₹415 Cr | down ₹13.2 Cr | Trimmed |
| Gland Pharma Limited | 6.63% | up 0.13 pts | ₹347 Cr | up ₹34.3 Cr | Added |
| Fortis Healthcare Limited | 5.95% | down 0.22 pts | ₹311 Cr | up ₹14.8 Cr | Added |
| Cash, TREPS & receivables | 5.91% | up 2.60 pts | ₹310 Cr | up ₹150 Cr | Added |
| Zydus Lifesciences Limited | 4.72% | down 1.81 pts | ₹247 Cr | down ₹66.8 Cr | Trimmed |
| Thyrocare Technologies Limited | 3.83% | down 0.19 pts | ₹200 Cr | up ₹7.4 Cr | Added |
| Narayana Hrudayalaya Limited | 3.35% | up 0.12 pts | ₹175 Cr | up ₹20.1 Cr | Added |
| Apollo Hospitals Enterprise Limited | 2.98% | up 0.98 pts | ₹156 Cr | up ₹59.8 Cr | Added |
| Abbott India Limited | 2.74% | up 0.50 pts | ₹143 Cr | up ₹35.7 Cr | Added |
| Jubilant Pharmova Limited | 2.51% | up 1.01 pts | ₹131 Cr | up ₹59.2 Cr | Added |
| Indoco Remedies Limited | 2.40% | up 0.22 pts | ₹126 Cr | up ₹20.7 Cr | Added |
| Torrent Pharmaceuticals Limited | 2.36% | up 0.79 pts | ₹123 Cr | up ₹48.1 Cr | Added |
| Sanofi India Limited | 1.95% | down 0.13 pts | ₹102 Cr | up ₹2.2 Cr | Added |
| Jubilant Ingrevia Limited | 0.84% | up 0.07 pts | ₹43.9 Cr | up ₹6.8 Cr | Added |
| Pfizer Limited | 0.49% | up 0.49 pts | ₹25.7 Cr | up ₹25.7 Cr | New |
| Healthcare Global Enterprises Limited | 0.41% | down 0.02 pts | ₹21.3 Cr | up ₹60 L | Added |
| Alkem Laboratories Limited | 0.04% | down <0.01 pts | ₹2.1 Cr | up ₹16 L | Added |
| Biocon Limited | 0.02% | down <0.01 pts | ₹1.1 Cr | up ₹2 L | Added |
What changed, Apr 2021 to May 2021
New New positions (1)
- Pfizer Limited0.5% · ₹25.7 Cr
Exited Exited (0)
None.
Added Biggest additions
- Apollo Hospitals Enterprise Limitedup ₹59.8 Cr (+0.98% pts)
- Jubilant Pharmova Limitedup ₹59.2 Cr (+1.01% pts)
- Torrent Pharmaceuticals Limitedup ₹48.1 Cr (+0.79% pts)
- Abbott India Limitedup ₹35.7 Cr (+0.50% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Apr 2021, the weight rose most in Healthcare Services (+1.2 pts) and Pharmaceuticals (+0.3 pts), and fell most in Pharmaceuticals & Biotechnology (−1.6 pts).
- Healthcare Services16.4% → 17.5%+1.2 pts
- Pharmaceuticals2.3% → 2.6%+0.3 pts
- Pharmaceuticals & Biotechnology80.6% → 79.0%−1.6 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | May 2020 | Nov 2020 | Feb 2021 | Apr 2021 | May 2021 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 80.3% | 79.0% | 79.0% | 80.6% | 79.0% |
| Healthcare Services | 17.4% | 18.8% | 18.3% | 16.4% | 17.5% |
| Pharmaceuticals | 2.3% | 2.2% | 2.4% | 2.3% | 2.6% |
| Chemicals & Petrochemicals | — | — | 0.3% | 0.8% | 0.9% |
Allocation in May 2021change vs Apr 2021
- Pharmaceuticals & Biotechnology (15)79.0%▼ 1.6 pts
- Healthcare Services (5)17.5%▲ 1.2 pts
- Pharmaceuticals (1)2.6%▲ 0.3 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, May 2021
5.9%
▲ 2.6 pts vs Apr 2021
- Cash alone
- 5.9%
- cash and net receivables
- A year earlier
- 0.9%
- May 2020 · now ▲ 5.0 pts
- Last 12 months
- 0.6% – 5.9%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.